FDA Approves Expanded Indication for Hyqvia to Treat Pediatric Primary Immunodeficiency
April 12th 2023During the 12-month trial period, Hyqvia was shown to be efficacious treating the occurrence of acute serious bacterial infections in children aged 2 through 16 years with primary immunodeficiency.
Read More
Real-World Efficacy, Safety of Tixagevimab/Cilgavimab in Patients With Cancer After EUA Revision
The role of monoclonal antibodies in minimizing COVID-19–related complications remains important to assess.
Read More
Encourage Patients to Call Between Visits for Better Toxicity Management During Treatment
April 7th 2023It would also be beneficial to include a patient’s entire healthcare team in this management strategy, said an expert at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference 2023 in Phoenix, Arizona.
Watch
Updates on 503A Compounding: Legal and Regulatory Developments
April 7th 2023Part 1 of this 2-part series examines USP <797> and <795> revisions for sterile and nonsterile compounding, veterinary compounding, FDA inspections of 503A pharmacies, and the interstate distribution of compounded prescriptions post Wellness Pharmacy v. FDA.
Read More